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Abstract
Purpose: To evaluate the performance linked to the consistency of a-Si EPID and ion-chamber array detectors for dose verifica-
tion in advanced radiotherapy. Methods: Planar measurements were made for 250 patients using an array of ion chamber and
a-Si EPID. For pre-treatment verification, the plans were generated on the phantom for re-calculation of doses. The
γ-evaluation method with the criteria: dose-difference (DD) ≤ 3% and distance-to-agreement (DTA) ≤ 3 mm was used for the
comparison of measurements. Also, the central axis (CAX) doses were measured using 0.125cc ion chamber and were compared
with the central chamber of array and central pixel correlated dose value from EPID image. Two types of statistical approaches
were applied for the analysis. Conventional statistics used analysis of variance (ANOVA) and unpaired t-test to evaluate the
performance of the detectors. And statistical process control (SPC) was utilized to study the statistical variation for the meas-
ured data. Control charts (CC) based on an average ( ), standard deviation ( ̅) and exponentially weighted moving averages
(EWMA) were prepared. The capability index (Cpm) was determined as an indicator for the performance consistency of the two
systems. Results: Array and EPID measurements had the average gamma pass rates as 99.9% ± 0.15% and 98.9% ± 1.06% respec-
tively. For the point doses, the 0.125cc chamber results were within 2.1% ± 0.5% of the central chamber of the array. Similarly,
CAX doses from EPID and chamber matched within 1.5% ± 0.3%. The control charts showed that both the detectors were per-
forming optimally and all the data points were within ± 5%. EWMA charts revealed that both the detectors had a slow drift
along the mean of the processes but was found well within ± 3%. Further, higher Cpm values for EPID demonstrate its higher
efficiency for radiotherapy techniques. Conclusion: The performances of both the detectors were seen to be of high quality ir-
respective of the radiotherapy technique. Higher Cpm values for EPID indicate its higher efficiency than array.
Keywords: a-Si EPID Dosimetry; γ – Analysis; Statistical Process Control; Capability Index
Introduction
In recent years, volumetric intensity-modulated arc therapy
(VMAT), static intensity modulated radiotherapy (s-IMRT)
and dynamic intensity modulated radiotherapy (d-IMRT)
has been adopted as the preferred option for the treatment
due to high dose conformity for the target and achieving
high dose gradients around the periphery of the target, thus
sparing the organs at risk (OAR).1-5 These advanced tech-
niques utilize the ability of multileaf collimator (MLC) to
generate the arbitrary shapes and computer algorithm to
develop treatment plan by optimization strategies such as
simulated annealing.6-8 This has led to an immense need for
quality control in such complex planning and delivery of
treatment plans. In the clinical setting, it is highly recom-
mended due to the fact that these errors could lead to fatal
consequences.9-10
The planar measurements in phantom geometry provide an
evaluation of the MLC and linear accelerator performance
for a patient specific plan. For the quantitative analysis, the
combination of dose-difference (DD) and distance-to-agree-
ment (DTA) is used to provide a single numerical quantity
known as the gamma (γ) index.11-13 It is a measure of disagre-
ement between calculated and measured planar region that
does not match to the acceptance criteria and indicate the
calculation quality in the region that pass the acceptance
criteria. In order to explore the stability and fluctuations in
the process of quality assurance for patient specific IMRT /
VMAT plans, the newer concept of statistical process con-
trol14-17 can be applied. It is a popular tool amongst the mod-
ern quality control techniques.18-19 Besides positional verifi-
cation20-21 and quality control of linac19,22-23, 24, several studies
have validated a-Si EPID for patient specific dosimetry.
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The present study quantifies the efficiency and consistency
of a-Si EPID as a planar detector when compared with
ion-chamber array over a large group of patients (N=250).
The primary goal of this study was to explore a met-
rics/method for evaluating consistency of the quality assur-
ance (QA) devices in a reliable manner. We have applied
traditional as well as the newer tools of statistical process
control (SPC) to the measurements undertaken prospectively
on the modern radiotherapy techniques using a ion chamber
array, a-Si EPID (for planar measurements) and ionization
chamber (for point dose measurements) on linear accelera-
tors. The purpose of utilizing control charts (CC) in this
work as a tool in radiotherapy was to monitor the perfor-
mance of the detectors (equipment) and delivery of radio-
therapy technique (process) for patient-by-patient basis in
advanced techniques.
Methods and Materials
Treatment planning, optimization and pre-treatment
verification procedures
Patients (N=250) were divided into four categories: brain
(n1= 62), head and neck (n2 = 62), thorax (n3 = 63) and pelvis
(n4 = 63). These patients were treated with advanced radia-
tion therapy techniques viz. s-IMRT or d-IMRT or VMAT
using 6 MV photon beams available at our center from Sep-
tember 2012 to January 2014. For our study purpose, we
planned all the 250 patients thrice: first for s-IMRT, second
for d-IMRT and third for VMAT planning. Treatment plan-
ning for s-IMRT, d-IMRT and VMAT were performed with
Monaco version 3.20.01. This system utilizes virtual energy
fluence (VEF) as a radiation source in combination with
X-Ray Voxel Monte Carlo (XVMC) method for dose compu-
tation. Kawrakow et al. developed VMC as a fast dose calcu-
lation engine for electron beams25, and later on it was ex-
tended to photon beams and was named as XVMC.26 The
process of optimization requires constraints as an objective
function for regions of interest (ROI): target and or-
gans-at-risk (OAR) volumes. For the pre-selected beams
angles/arcs, system optimizes fluence distribution and gener-
ates MLC segments based on beamlets. Further, the segment
weight optimization (SWO) algorithm optimizes the number
of segments to achieve the desired dose distribution. The
dose calculation cube voxel size and the statistical uncer-
tainty of the XVMC dose calculation used in this study were
3 × 3 × 3 mm3 and 1%, respectively.
For the patient specific pretreatment quality assurance for
s-IMRT, d-IMRT and VMAT were performed systematically
twice with 2D array (PTW, Freiburg) and a-Si EPID.21-24
These detectors worked in the integrated mode, so the flu-
ence delivered with each and every beam and segment was
accumulated in a single frame. The measured fluence was
compared with the TPS calculated fluence. The clinical tol-
erance,    ArrayArray %100%  and
EPIDEPID )(100(%) % as per ICRU-83 was taken as < ±
3 % irrespective of the anatomical site and the type of the
technique used.
Statistical analysis: traditional and statistical process
control
In the present work the conventional statistic and the statis-
tical process control as the modern quality management tool
was applied, to analyze the consistency of a-Si EPID and
ion-chamber array detector systems. The data characteriza-
tion included the identification of the statistical distribution
that fits the data appropriately. Data points were plotted as
histogram and were checked for its goodness of fit (GoF) to a
normal distribution. The (Jarque-Bera) JB statistics28 was
selected since it has a two-sided goodness of fit test, suitable
when the sample is tested against the unknown population
and also the population parameters are required to be esti-
mated. It is specifically designed as the alternative to the
Pearsons system of distribution. The JB test evaluates the
null hypothesis (H0) that the all two set of samples ∆Array and
∆EPID follow a normal distribution and quantifies the differ-
ences between the 2 samples and normal distribution using
the sample skewness and kurtosis. The test statistics JB is
defined as   

  22 34
1
6 ks
nJB Where, n is the number of
observations, s is the sample skewness and k is the sample





























































where, 3ˆ and 4ˆ are the estimates of third and fourth cen-
tral moments, respectively, x is the sample mean, and 2ˆ is
the estimate of the second central moment, the variance.
The difference between the detectors used for different
modern radiotherapy techniques was evaluated using hy-
pothesis testing. The t-test analysis was considered an ap-
propriate test for judging the significance of a sample mean,
in case when population variance is not known. Further, the
unpaired t-test was used for two samples which are not re-
lated to each other.29 This testing was performed on the
three independent groups viz. s-IMRT, d-IMRT and VMAT,
and for each group the measurement was performed twice,
first by 2D array (PTW, Freiburg) and second by a-Si EPID.
The analysis of variance (ANOVA) was used to compare the
means of different groups (≤ 2) of data: three groups were
s-IMRT, d-IMRT and VMAT. The comparison was done
using ANOVA independently for each of the groups between
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δIC, ∆Array and ∆EPID measurements. ANOVA is a statistical
technique that characterizes the data in groups and compares
the mean and variance of the data among the categories.29
p-values of the distribution were used to evaluate the statis-
tical significance of difference invariability in data between
the different categories. In order to identify the differences
the means of two or more groups at a time, the
method is utilized to interpret and confirm the results of
ANOVA. For comparison between the measurements we
used software Prism version 6 from GraphPad and p ≤ 0.05
was considered as significant.
The newest approach of data analysis is based on the applied
concepts of statistical process control (SPC). It is commonly
used in engineering and industrial applications to proactively
monitor the process performance and also helps in focusing
on the continuous improvement in the process. Control
charts are amongst the quality control tools for SPC to mon-
itor process variation. There are three types of charts: ,̅ and EWMA. The chart consists of an upper control
(UCL), centre line (CL), lower control limit (LCL) and the
data points. The LCL and UCL are usually set at a distance of
standard deviations (σ) above and below the CL, the average
of the process. The first 50 data points from array γ%<1 and








Where, MR is the value between two consecutive points of
percentage (%) of gamma pass (MRi = |Δi – Δi-1|). Δ is the
average of % difference in gamma pass and RM is the aver-
of moving-range of % difference in gamma pass in the sub-
group. The constant d2 depends on the total number of
(n) in subgroup. In the present case, n is equal to 2, so d2 is
1.128.29-30 The percentage (%) differences in gamma pass of
s-IMRT, d-IMRT and VMAT QA plans measured by
2D-Array ( arrayγ%<1) and  a-Si EPID ( EPIDγ%<1) were plot-
ted on control charts for  the individual patients. The
chart considers each patient’s quality control result as an
individual value of the QA process. Although charts are
widely used, but to determine the process variability or
standard deviation(s) graphically, the ̅ charts are utilized.
The baseline values for the ̅ chart were again derived from



















The s is the average standard deviation of the sample, c4 is
the function of available groups under consideration. The
value of c4 can be determined from the standard tables
available in textbooks.29-30 In the present study, for the spe-
cific type of radiotherapy delivery the measurements from
two detectors 2D Array (PTW, Freiburg) and a-Si EPID were
compared. The value of c4 was taken as 0.7979. and ̅
charts are the first phase tools where the process is under the
establishment and is experiencing assignable causes for vari-
ation. But after the satisfactory implementation of the pro-
cess, the and ̅ charts become relatively insensitive to
small process shifts (≤ ±1.5 σ). In order to monitor the pr o-
quality and performance in the long run, the exponentially
weighted moving averages (EWMA) type of control chart
proves to be useful.29-30 A EWMA chart is the time-weighted
control chart, it weighs the sample in geometrically decreas-
ing order so that the most recent sample are weighted most
highly while the most distant sample contribute very little.
The design parameters of the EWMA control chart are  11  iii zxz 
Where, zi is the exponentially weighted moving average, λ is
an age of the sample and with value between 0 and 1. The
starting value of λ was taken as 0.3.35 zi in the beginning z0=
x .
    iLsUCL 20 112  
    iLsLCL 20 112  
0CL
Where μ0 is the mean of the preliminary data taken as the
starting value, L is the width of the control limit. The value
of L was taken as 3.31
Process capability analysis is a quantitative method of ana-
lyzing the process stability and capability in overall quality
management program. This index (Cpm) is the measure of
process performance within the specification limits. Funda-
mentally, capability indexes are used to estimate the compe-
tence between the production tool and the quality targeted
for the product. In radiotherapy scenario, the production
refers to a-Si EPID as a detector tool and the product refers
the gamma value obtained as the result of patient specific
quality assurance activity. It accounts for the data dispersion
and determines the closeness of the data ( ) to the process
mean (T). Cpm takes into account for both the proximity of
process to the target value as well as the magnitude of the





Where, (USL – LSL) is the difference between the upper and
lower specification clinical limit, σ2 is the variance, X is the
process mean and T is the target value of the process. T is 0%
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because the target for the QA process is 100% matching of
fluence. The Cpmvalue greater than and equal to 1.33 indicate
that the process is operating optimally.33 The higher the
of Cpm, the higher is the efficiency of the process. This is due
to the fact that the loss function34 appears in the
as  22 TX  .
Results
Array and EPID based two dimensional measurements had
the mean gamma pass rates as 99.9% ± 0.15% and 98.9 ±
1.06% respectively. Table1 provide the details of complete
sample of 250 plans for different radiotherapy techniques
viz. s-IMRT, d-IMRT and VMAT. For the point dose meas-
urements, the ion chamber results were found to be within
2.1% ± 0.5% of the central chamber of the array. Similarly,
the central axis point doses from EPID and ion chamber
matched within 1.5% ± 0.3%.
TABLE: Summary of the conventional statistics for s-IMRT, d-IMRT
& VMAT.
S.N Parameter s-IMRT d-IMRT VMAT
1 Total no. of plans 250 250 250
2 Total no. of beams/arcs 1750 1793 263
3 Total no. of segments/ports 189548 151258 114190
4 Total no. of monitor units 989731 866354 912850
5 Mean of ∆Array(%) 1.225 1.29 1.2592
6 Standard deviation of ∆Array(%) 0.884 0.962 0.978
7 Mean of ∆EPID(%) 1.27 1.15 1.2662
8 Standard deviation of ∆EPID(%) 0.912 0.199 0.148
The Jarque-Bera (JB) statistics were implemented for all
three techniques; the measurements for ∆Array and ∆EPIDwere
distributed normally.
The Table 2 illustrates skewness and kurtosis for the three
samples. For 1500 plans, a-Si EPID, detector array measured
and planning system calculated photon fluence agrees within
the action level limits. The observed mean ± standard devia-
tion values for the gamma analysis were EPIDγmean = 0.81±0.06,
EPIDγmax = 1.46±0.78 and EPIDγ%≤1= 99.66±1.54 and arrayγmean =
0.7±0.05, arrayγmax = 1.3±0.08 and arrayγ%<1= 98.56±1.29. Among
all the plans γmax was found to be consistently lower in array
then a-Si EPID. It was seen that the variation of γmax and γ% ≤1
estimated from array and a-Si EPID for VMAT was 5.6% and
2.4% plans, respectively. However, the variation in γmean was
seen only in 1% cases. The highest values of γ%<1 was ob-
served in VMAT plans when measured using a-Si EPID. For
1500 plans, EPID measurements had higher γmean than the
array measurements. The statistical analysis for γ-evaluation
performed using array and EPID with ANOVA showed the
average of γ values do not differ much from each other.
Thus, it implies that there are no significant differences
among the performance of array and EPID. The unpaired
t-test for these measurements performed by a-Si EPID and
array for s-IMRT, d-IMRT and VMAT were assessed inde-
pendently and individually. Results indicate that within all
the individual groups there were no statistically significant
differences observed with p > 0.05 in each group. The per-
formances of both the detectors were seen to be of high
quality irrespective of the radiotherapy techniques.
In order to assess the variability of the patient specific quali-
ty assurance processes for s-IMRT, d-IMRT and VMAT for
the measurements performed by array and a-Si EPID, the
concepts of statistical process control (SPC) were also im-
plemented using , ̅ and EWMA control charts. The CL,
UCL and LCL of the chart were evaluated from first 50
cases for analyzing 250 s-IMRT, d-IMRT and VMAT for both
the array and a-Si EPID measurements. The value of UCL
has been fixed to 100% because it is the maximum value for
γ%<1. The charts are presented in Figure 1(a-c) for
s-IMRT, d-IMRT and VMAT. The ̅ charts were also gen-
erated for the collected data to monitor the process variabil-
ity over time.
The ̅ charts are presented in Figure 2(a-c) for s-IMRT,
d-IMRT and VMAT. The EWMA charts were also generated
to monitor the variability in the process mean over a partic-
ular period. The performance of the process can be reviewed
weekly to find out the trends or drifts in process. EWMA
chart is sensitive even lesser than 1.5σ level variation. The
EWMA charts are presented in Figure 3. The smooth trend
was observed in all the processes for present study indicating
the processes were found well within the control limits. Like
conventional statistical analysis results, the CC analysis was
also suggestive of the fact that for all the advanced radio-
therapy techniques both array and a-Si EPID based planar
measurements were performing optimally.
Another approach of evaluating the capability indices was
applied to the collected data. The values of this index are
mentioned in Table 2. The values of this index for all the
different combinations were found to be < 1.33, which en-
sures a good level of quality for the processes. For all the
measurements performed with a-Si EPID, irrespective of
radiotherapy technique, obtained a better and higher value
of Cpm. It was also seen that the highest value of Cpm was
obtained for the combination of VMAT QA plans measured
using a-Si EPID.
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TABLE 2: Mean ±1.96σ of γ% pass, Skewness, Kurtosis and capability index Cpm for the array and a-Si EPID measurements for s-IMRT, d-IMRT
and VMAT
VMAT d-IMRT s-IMRT
EPID Array EPID Array EPID Array
Mean (γ%pass ) 98.64 98.58 98.53 98.47 98.68 98.55
Standard deviation (σ) (γ% pass ) 1.18 1.20 1.28 1.22 1.38 1.29
No. of patients in the range Mean±1.96σ 248.0 239.0 246.0 235.0 237.0 236.0
% of patients in the range mean±1.96σ 99.20 95.60 98.40 94.00 94.80 94.40
Skewness 0.49 0.51 0.67 0.58 0.77 0.75
Kurtosis -0.88 -0.78 -0.26 -0.49 -0.43 -0.25
Normality Test Pass Pass Pass Pass Pass Pass
Cpm values 1.55 1.45 1.58 1.46 1.57 1.43
FIG. 1(a-c): control charts for s-IMRT, d-IMRT and VMAT QA measurements by a-Si EPID and array
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FIG. 2(a-c): ̅ control charts for s-IMRT, d-IMRT and VMAT QA measurements by a-Si EPID and array
FIG. 3: EWMA control charts for s-IMRT, d-IMRT and VMAT QA measurements by a-Si EPID and array
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Discussion
The complex planning and timely response of the extensive
hardware in the modern radiotherapy techniques has made
patient specific QA a standard of practice.10 In our institute,
the pre-treatment verification of the s-IMRT, d-IMRT and
VMAT plans have been carried out using ion chamber array
and a-Si EPID routinely. The array is calibrated for measur-
ing absolute dose using standard field size (10 cm × 10 cm for
Synergy and 10.4 cm × 10.4 cm for Axesse) and routinely
evaluates the agreement between TPS calculated and ion
chamber array measured dose. Portal dosimetry as a
pre-treatment QA tool for advanced radiotherapy techniques
is in its infancy although few centers have been using it
mostly with their indigenously developed software.22,35-37 In
the present work the a-Si EPID captured fluence was nor-
malized with the computed data at the isocentric pixel for
cGy conversion in verisoft software (PTW, Freiburg). This
normalized fluence was then compared with the calculated
fluence at couch level on the 5 cm thick water equivalent
slab phantom. We are reporting array and a-Si EPID com-
parative results for s-IMRT, d-IMRT and VMAT using PTW
Verisoft software for gamma analysis. Our results shows very
good agreement between calculated and measured dose dis-
tribution in all plans with overall mean ± SD gamma values
as shown in Table 2. Recently, portal dosimetry results from
Varian were reported from Howell.22 The authors reported
the results from 152 IMRT plans that the overall mean ± SD
γmax = 2.4 ± 0.8, γavg =0.33 ± 0.13 and γ% > 1 = 4.1% ± 6.2%.
Also, for complex head and neck planning, Howell et al. has
reported higher gamma values. Our results are in agreement
with this study.
The advantage of control charts is that it is instrumental in
accessing the performance of the process/equipment over the
time and also facilitating the user to identify the causative
factor of variation in the process/equipment. Originally,
control charts are employed in the industrial applications to
maintain the quality of each individual product but the sim-
ilar concept can be extended to the radiation oncology ser-
vices.18 With the implementation of such a concept in radia-
tion oncology, there will be a paradigm shift towards im-
provement in patient care. For the advanced technologies in
radiation therapy, the minimum requirement is to ensure
their dosimetric accuracy and needs to be determined for
every patient individually. Pawlicki14, 15 have identified the
utilization of control charts for monitoring the performance
of linear accelerator for the measurements of output and
beam characteristics (flatness and symmetry) for 10 MV
photon beam. Gerard16 have studied total 119 dynamic IMRT
head and neck and prostate cases retrospectively, and have
shown the usage of all three types of control charts and per-
formance linked indices for point dose measurements.
The overall results of patient-specific QA for advanced radi-
otherapy techniques using array and a-Si EPID are compara-
ble to each other. The γ measurements using a-Si EPID pro-
duced higher results than array. The charts also graphically
illustrated that all the processes were performing optimally.
The statistical reliability of the detectors in advanced radio-
therapy techniques was determined using Cpm index. The Cpm
values imply that all the QA processes irrespective of the
techniques and detector choice were performing optimally.
Higher the value of Cpm < 1.33, the efficient is the perfor-
mance of the equipment. The a-Si EPID based dosimetry
process obtained higher value of Cpm than that of the detec-
tor array.
Conclusion
a-Si based EPID and array were found to be consistent in
quality performance for modern radiotherapy dosimetry.
Higher values for EPIDCpm indicate higher statistical reliability
and efficiency for EPID than the array based measurements.
Statistical process control is realized as the scientific and
pictorial way of analyzing the real time data and simul-
taneously provides the immediate feedback for the newer
incoming data points derived from quality assurance re-
sults of s-IMRT/d-IMRT/VMAT.
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